RNA Interference (RNAi) Drug Delivery Market Report

Global and Region RNA Interference (RNAi) Drug Delivery Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 30, 2022
  • PAGES：193
  • REPORT CODE：GMM911689
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of RNA Interference (RNAi) Drug Delivery market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of RNA Interference (RNAi) Drug Deliverymarket, defines the market attractiveness level of RNA Interference (RNAi) Drug Delivery market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of RNA Interference (RNAi) Drug Delivery industry, describes the types of RNA Interference (RNAi) Drug Delivery market, the applications of major players and the market size, and deeply analyzes the current situation of the global RNA Interference (RNAi) Drug Delivery market and the development prospects and opportunities of RNA Interference (RNAi) Drug Delivery industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global RNA Interference (RNAi) Drug Delivery market in Chapter 13.

    By Player:

    • Traversa Therapeutics Inc

    • Calondo Pharmaceuticals Inc

    • RXi Pharmaceuticals Corp

    • Sirnaomics Inc

    • Silence Therapeutics plc

    • Tacere Therapeutics Inc

    • Dicerna Pharmaceuticals Inc

    • Alnylam Pharmaceuticals Inc

    • Metabolic disorders

    • Quark Pharmaceuticals Inc

    • Marina Biotech Inc

    • Access Pharmaceuticals Inc

    • Merck & Co Inc

    • PhaseRx Inc

    By Type:

    • Nanoparticle Drug Delivery Technology

    • Pulmonary Drug Delivery Technology

    • Nucleic Acid Drug Delivery Technology

    • Aptamer Drug Delivery Technology

    By End-User:

    • Infectious Diseases

    • Cardiology

    • Oncology

    • Neurology

    • Ophthalmology

    • Metabolic Disorders

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 RNA Interference (RNAi) Drug Delivery Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 RNA Interference (RNAi) Drug Delivery Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 RNA Interference (RNAi) Drug Delivery Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 RNA Interference (RNAi) Drug Delivery Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise RNA Interference (RNAi) Drug Delivery Market Analysis and Outlook to 2022

    • 7.1 Global RNA Interference (RNAi) Drug Delivery Consumption (2017-2022)

    • 7.2 United States RNA Interference (RNAi) Drug Delivery Consumption (2017-2022)

    • 7.3 Europe RNA Interference (RNAi) Drug Delivery Consumption (2017-2022)

    • 7.4 China RNA Interference (RNAi) Drug Delivery Consumption (2017-2022)

    • 7.5 Japan RNA Interference (RNAi) Drug Delivery Consumption (2017-2022)

    • 7.6 India RNA Interference (RNAi) Drug Delivery Consumption (2017-2022)

    • 7.7 South Korea RNA Interference (RNAi) Drug Delivery Consumption (2017-2022)

    8 Region and Country-wise RNA Interference (RNAi) Drug Delivery Market Analysis and Outlook to 2028

    • 8.1 Global RNA Interference (RNAi) Drug Delivery Consumption Forecast (2022-2028)

    • 8.2 United States RNA Interference (RNAi) Drug Delivery Consumption Forecast (2022-2028)

    • 8.3 Europe RNA Interference (RNAi) Drug Delivery Consumption Forecast (2022-2028)

    • 8.4 China RNA Interference (RNAi) Drug Delivery Consumption Forecast (2022-2028)

    • 8.5 Japan RNA Interference (RNAi) Drug Delivery Consumption Forecast (2022-2028)

    • 8.6 India RNA Interference (RNAi) Drug Delivery Consumption Forecast (2022-2028)

    • 8.7 South Korea RNA Interference (RNAi) Drug Delivery Consumption Forecast (2022-2028)

    9 Global RNA Interference (RNAi) Drug Delivery Market Outlook by Types and Applications to 2022

    • 9.1 Global RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Nanoparticle Drug Delivery Technology Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Pulmonary Drug Delivery Technology Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Nucleic Acid Drug Delivery Technology Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Aptamer Drug Delivery Technology Consumption and Growth Rate (2017-2022)

    • 9.2 Global RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Infectious Diseases Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Cardiology Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Oncology Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Neurology Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Ophthalmology Consumption and Growth Rate (2017-2022)

      • 9.2.6 Global Metabolic Disorders Consumption and Growth Rate (2017-2022)

    10 Global RNA Interference (RNAi) Drug Delivery Market Outlook by Types and Applications to 2028

    • 10.1 Global RNA Interference (RNAi) Drug Delivery Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Nanoparticle Drug Delivery Technology Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Pulmonary Drug Delivery Technology Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Nucleic Acid Drug Delivery Technology Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Aptamer Drug Delivery Technology Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global RNA Interference (RNAi) Drug Delivery Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Infectious Diseases Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Cardiology Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Oncology Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Neurology Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.5 Global Ophthalmology Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.6 Global Metabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    11 Global RNA Interference (RNAi) Drug Delivery Import and Export Analysis (Top 5 Countries)

    • 11.1 Global RNA Interference (RNAi) Drug Delivery Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global RNA Interference (RNAi) Drug Delivery Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 RNA Interference (RNAi) Drug Delivery Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global RNA Interference (RNAi) Drug Delivery Market Competitive Analysis

    • 14.1 Traversa Therapeutics Inc

      • 14.1.1 Traversa Therapeutics Inc Company Details

      • 14.1.2 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • 14.2 Calondo Pharmaceuticals Inc

      • 14.2.1 Calondo Pharmaceuticals Inc Company Details

      • 14.2.2 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • 14.3 RXi Pharmaceuticals Corp

      • 14.3.1 RXi Pharmaceuticals Corp Company Details

      • 14.3.2 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Product and Service

    • 14.4 Sirnaomics Inc

      • 14.4.1 Sirnaomics Inc Company Details

      • 14.4.2 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • 14.5 Silence Therapeutics plc

      • 14.5.1 Silence Therapeutics plc Company Details

      • 14.5.2 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Product and Service

    • 14.6 Tacere Therapeutics Inc

      • 14.6.1 Tacere Therapeutics Inc Company Details

      • 14.6.2 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • 14.7 Dicerna Pharmaceuticals Inc

      • 14.7.1 Dicerna Pharmaceuticals Inc Company Details

      • 14.7.2 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • 14.8 Alnylam Pharmaceuticals Inc

      • 14.8.1 Alnylam Pharmaceuticals Inc Company Details

      • 14.8.2 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • 14.9 Metabolic disorders

      • 14.9.1 Metabolic disorders Company Details

      • 14.9.2 Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Metabolic disorders RNA Interference (RNAi) Drug Delivery Product and Service

    • 14.10 Quark Pharmaceuticals Inc

      • 14.10.1 Quark Pharmaceuticals Inc Company Details

      • 14.10.2 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • 14.11 Marina Biotech Inc

      • 14.11.1 Marina Biotech Inc Company Details

      • 14.11.2 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • 14.12 Access Pharmaceuticals Inc

      • 14.12.1 Access Pharmaceuticals Inc Company Details

      • 14.12.2 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • 14.13 Merck & Co Inc

      • 14.13.1 Merck & Co Inc Company Details

      • 14.13.2 Merck & Co Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Merck & Co Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • 14.14 PhaseRx Inc

      • 14.14.1 PhaseRx Inc Company Details

      • 14.14.2 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of RNA Interference (RNAi) Drug Delivery

    • Figure RNA Interference (RNAi) Drug Delivery Picture

    • Table Global RNA Interference (RNAi) Drug Delivery Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global RNA Interference (RNAi) Drug Delivery Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global RNA Interference (RNAi) Drug Delivery Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global RNA Interference (RNAi) Drug Delivery Consumption by Country (2017-2022)

    • Figure United States RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2017-2022)

    • Table Europe RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2017-2022)

    • Figure China RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2017-2022)

    • Figure Japan RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2017-2022)

    • Figure India RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2017-2022)

    • Figure South Korea RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2017-2022)

    • Figure Global RNA Interference (RNAi) Drug Delivery Consumption Forecast by Country (2022-2028)

    • Figure United States RNA Interference (RNAi) Drug Delivery Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe RNA Interference (RNAi) Drug Delivery Consumption Forecast and Growth Rate (2022-2028)

    • Figure China RNA Interference (RNAi) Drug Delivery Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan RNA Interference (RNAi) Drug Delivery Consumption Forecast and Growth Rate (2022-2028)

    • Figure India RNA Interference (RNAi) Drug Delivery Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea RNA Interference (RNAi) Drug Delivery Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Nanoparticle Drug Delivery Technology Consumption and Growth Rate (2017-2022)

    • Figure Global Pulmonary Drug Delivery Technology Consumption and Growth Rate (2017-2022)

    • Figure Global Nucleic Acid Drug Delivery Technology Consumption and Growth Rate (2017-2022)

    • Figure Global Aptamer Drug Delivery Technology Consumption and Growth Rate (2017-2022)

    • Figure Global Infectious Diseases Consumption and Growth Rate (2017-2022)

    • Figure Global Cardiology Consumption and Growth Rate (2017-2022)

    • Figure Global Oncology Consumption and Growth Rate (2017-2022)

    • Figure Global Neurology Consumption and Growth Rate (2017-2022)

    • Figure Global Ophthalmology Consumption and Growth Rate (2017-2022)

    • Figure Global Metabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Global Nanoparticle Drug Delivery Technology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pulmonary Drug Delivery Technology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Nucleic Acid Drug Delivery Technology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Aptamer Drug Delivery Technology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Infectious Diseases Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cardiology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oncology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Neurology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ophthalmology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Metabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Table Global RNA Interference (RNAi) Drug Delivery Import by Region (Top 5 Countries) (2017-2028)

    • Table Global RNA Interference (RNAi) Drug Delivery Export by Region (Top 5 Countries) (2017-2028)

    • Table Traversa Therapeutics Inc (Foundation Year, Company Profile and etc.)

    • Table Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • Table Calondo Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • Table RXi Pharmaceuticals Corp (Foundation Year, Company Profile and etc.)

    • Table RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Product and Service

    • Table Sirnaomics Inc (Foundation Year, Company Profile and etc.)

    • Table Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • Table Silence Therapeutics plc (Foundation Year, Company Profile and etc.)

    • Table Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Product and Service

    • Table Tacere Therapeutics Inc (Foundation Year, Company Profile and etc.)

    • Table Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • Table Dicerna Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • Table Alnylam Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • Table Metabolic disorders (Foundation Year, Company Profile and etc.)

    • Table Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table Metabolic disorders RNA Interference (RNAi) Drug Delivery Product and Service

    • Table Quark Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • Table Marina Biotech Inc (Foundation Year, Company Profile and etc.)

    • Table Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • Table Access Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • Table Merck & Co Inc (Foundation Year, Company Profile and etc.)

    • Table Merck & Co Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck & Co Inc RNA Interference (RNAi) Drug Delivery Product and Service

    • Table PhaseRx Inc (Foundation Year, Company Profile and etc.)

    • Table PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Value and Gross Profit (2017-2022)

    • Table PhaseRx Inc RNA Interference (RNAi) Drug Delivery Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US